Department of Chemistry, University of Life Sciences, Akademicka 15, 20-950 Lublin, Poland.
Eur J Med Chem. 2013 Apr;62:311-9. doi: 10.1016/j.ejmech.2012.12.060. Epub 2013 Jan 11.
In this paper a series of new 1,3,4-thiadiazole derivatives has been designed, synthesized and evaluated as the acetyl- and butyrylcholinesterase inhibitors. Some analogues showed promising inhibition of both enzymes in vitro in the nM range. Generally, inhibitory potency of compounds was stronger against AChE than BuChE, and one of them was 1154-fold more active inhibiting AChE (IC50 = 0.17 μM) than BuChE. The kinetic studies showed that one of the most active analogues 8 (IC50 = 0.09 μM, AChE) acted as a non-competitive AChE inhibitor and was characterized by the high selectivity index (300). The other derivative (1) exhibited a mixed-type of AChE inhibition. Docking simulations enabled the detection of key binding interactions of the compounds with AChE and revealed that they occupied mainly the catalytic active site. The scoring function for the novel compounds was similar or higher than for the reference inhibitor. Additionally, based on Lipinski and other filters, the drug-likeness of compounds was assessed. They revealed that the compounds possess properties which can suggest the favourable pharmacokinetics in the human body after oral admission.
在本文中,设计、合成并评价了一系列新的 1,3,4-噻二唑衍生物,作为乙酰胆碱酯酶和丁酰胆碱酯酶抑制剂。一些类似物在体外以纳摩尔范围显示出对两种酶有良好的抑制作用。一般来说,化合物对 AChE 的抑制活性强于 BuChE,其中一种对 AChE 的抑制活性比 BuChE 高 1154 倍(IC50 = 0.17 μM)。动力学研究表明,最活跃的类似物之一 8(IC50 = 0.09 μM,AChE)作为非竞争性 AChE 抑制剂,具有较高的选择性指数(300)。另一种衍生物(1)表现出混合类型的 AChE 抑制作用。对接模拟使化合物与 AChE 的关键结合相互作用得以检测,并表明它们主要占据催化活性部位。新型化合物的评分函数与参考抑制剂相似或更高。此外,基于 Lipinski 等筛选标准,评估了化合物的类药性。结果表明,这些化合物具有在口服给药后在人体内具有良好的药代动力学性质的特征。